Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 90

1.

Immunological Assays used to Support Efficacy of Zika Virus Vaccines.

Eckels KH, De La Barrera RA, Putnak JR.

Trop Med Infect Dis. 2019 Jun 28;4(3). pii: E97. doi: 10.3390/tropicalmed4030097. Review.

2.

Cell-mediated immune responses to different formulations of a live-attenuated tetravalent dengue vaccine candidate in subjects living in dengue endemic and non-endemic regions.

Moris P, Bauer KM, Currier JR, Friberg H, Eckels KH, Esquilin IO, Gibbons RV, Innis BL, Jarman RG, Simasathien S, Sun P, Thomas SJ, Watanaveeradej V.

Hum Vaccin Immunother. 2019 Mar 4:1-16. doi: 10.1080/21645515.2019.1581536. [Epub ahead of print]

PMID:
30829100
3.

Phase I Randomized Study of a Tetravalent Dengue Purified Inactivated Vaccine in Healthy Adults from Puerto Rico.

Diaz C, Lin L, Martinez LJ, Eckels KH, Campos M, Jarman RG, De La Barrera R, Lepine E, Toussaint JF, Febo I, Innis BL, Thomas SJ, Schmidt AC.

Am J Trop Med Hyg. 2018 May;98(5):1435-1443. doi: 10.4269/ajtmh.17-0627. Epub 2018 Mar 1.

4.

Durability and correlates of vaccine protection against Zika virus in rhesus monkeys.

Abbink P, Larocca RA, Visitsunthorn K, Boyd M, De La Barrera RA, Gromowski GD, Kirilova M, Peterson R, Li Z, Nanayakkara O, Nityanandam R, Mercado NB, Borducchi EN, Chandrashekar A, Jetton D, Mojta S, Gandhi P, LeSuer J, Khatiwada S, Lewis MG, Modjarrad K, Jarman RG, Eckels KH, Thomas SJ, Michael NL, Barouch DH.

Sci Transl Med. 2017 Dec 13;9(420). pii: eaao4163. doi: 10.1126/scitranslmed.aao4163. Erratum in: Sci Transl Med. 2018 Jul 18;10(450):.

5.

Preliminary aggregate safety and immunogenicity results from three trials of a purified inactivated Zika virus vaccine candidate: phase 1, randomised, double-blind, placebo-controlled clinical trials.

Modjarrad K, Lin L, George SL, Stephenson KE, Eckels KH, De La Barrera RA, Jarman RG, Sondergaard E, Tennant J, Ansel JL, Mills K, Koren M, Robb ML, Barrett J, Thompson J, Kosel AE, Dawson P, Hale A, Tan CS, Walsh SR, Meyer KE, Brien J, Crowell TA, Blazevic A, Mosby K, Larocca RA, Abbink P, Boyd M, Bricault CA, Seaman MS, Basil A, Walsh M, Tonwe V, Hoft DF, Thomas SJ, Barouch DH, Michael NL.

Lancet. 2018 Feb 10;391(10120):563-571. doi: 10.1016/S0140-6736(17)33106-9. Epub 2017 Dec 5.

6.

Phase 1 Randomized Study of a Tetravalent Dengue Purified Inactivated Vaccine in Healthy Adults in the United States.

Schmidt AC, Lin L, Martinez LJ, Ruck RC, Eckels KH, Collard A, De La Barrera R, Paolino KM, Toussaint JF, Lepine E, Innis BL, Jarman RG, Thomas SJ.

Am J Trop Med Hyg. 2017 Jun;96(6):1325-1337. doi: 10.4269/ajtmh.16-0634.

7.

Dengue Virus Exposures Among Deployed U.S. Military Personnel.

Hesse EM, Martinez LJ, Jarman RG, Lyons AG, Eckels KH, De La Barrera RA, Thomas SJ.

Am J Trop Med Hyg. 2017 May;96(5):1222-1226. doi: 10.4269/ajtmh.16-0663. Epub 2017 Feb 13.

8.

Rapid development of a DNA vaccine for Zika virus.

Dowd KA, Ko SY, Morabito KM, Yang ES, Pelc RS, DeMaso CR, Castilho LR, Abbink P, Boyd M, Nityanandam R, Gordon DN, Gallagher JR, Chen X, Todd JP, Tsybovsky Y, Harris A, Huang YS, Higgs S, Vanlandingham DL, Andersen H, Lewis MG, De La Barrera R, Eckels KH, Jarman RG, Nason MC, Barouch DH, Roederer M, Kong WP, Mascola JR, Pierson TC, Graham BS.

Science. 2016 Oct 14;354(6309):237-240. Epub 2016 Sep 22.

9.

Protective efficacy of multiple vaccine platforms against Zika virus challenge in rhesus monkeys.

Abbink P, Larocca RA, De La Barrera RA, Bricault CA, Moseley ET, Boyd M, Kirilova M, Li Z, Ng'ang'a D, Nanayakkara O, Nityanandam R, Mercado NB, Borducchi EN, Agarwal A, Brinkman AL, Cabral C, Chandrashekar A, Giglio PB, Jetton D, Jimenez J, Lee BC, Mojta S, Molloy K, Shetty M, Neubauer GH, Stephenson KE, Peron JP, Zanotto PM, Misamore J, Finneyfrock B, Lewis MG, Alter G, Modjarrad K, Jarman RG, Eckels KH, Michael NL, Thomas SJ, Barouch DH.

Science. 2016 Sep 9;353(6304):1129-32. doi: 10.1126/science.aah6157. Epub 2016 Aug 4.

10.

Vaccine protection against Zika virus from Brazil.

Larocca RA, Abbink P, Peron JP, Zanotto PM, Iampietro MJ, Badamchi-Zadeh A, Boyd M, Ng'ang'a D, Kirilova M, Nityanandam R, Mercado NB, Li Z, Moseley ET, Bricault CA, Borducchi EN, Giglio PB, Jetton D, Neubauer G, Nkolola JP, Maxfield LF, De La Barrera RA, Jarman RG, Eckels KH, Michael NL, Thomas SJ, Barouch DH.

Nature. 2016 Aug 25;536(7617):474-8. Epub 2016 Jun 28.

11.

Long-Term Safety and Immunogenicity of a Tetravalent Live-Attenuated Dengue Vaccine and Evaluation of a Booster Dose Administered to Healthy Thai Children.

Watanaveeradej V, Simasathien S, Mammen MP, Nisalak A, Tournay E, Kerdpanich P, Samakoses R, Putnak RJ, Gibbons RV, Yoon IK, Jarman RG, De La Barrera R, Moris P, Eckels KH, Thomas SJ, Innis BL.

Am J Trop Med Hyg. 2016 Jun 1;94(6):1348-1358. doi: 10.4269/ajtmh.15-0659. Epub 2016 Mar 28.

12.

A Phase II, Randomized, Safety and Immunogenicity Trial of a Re-Derived, Live-Attenuated Dengue Virus Vaccine in Healthy Children and Adults Living in Puerto Rico.

Bauer K, Esquilin IO, Cornier AS, Thomas SJ, Quintero Del Rio AI, Bertran-Pasarell J, Morales Ramirez JO, Diaz C, Carlo S, Eckels KH, Tournay E, Toussaint JF, De La Barrera R, Fernandez S, Lyons A, Sun W, Innis BL.

Am J Trop Med Hyg. 2015 Sep;93(3):441-453. doi: 10.4269/ajtmh.14-0625. Epub 2015 Jul 14.

13.

Safety and Immunogenicity of a Dengue Virus Serotype-1 Purified-Inactivated Vaccine: Results of a Phase 1 Clinical Trial.

Martinez LJ, Lin L, Blaylock JM, Lyons AG, Bauer KM, De La Barrera R, Simmons M, Jarman RG, Currier JR, Friberg H, Danko JR, Teneza-Mora NC, Putnak JR, Eckels KH, Thomas SJ.

Am J Trop Med Hyg. 2015 Sep;93(3):454-460. doi: 10.4269/ajtmh.14-0819. Epub 2015 Jul 6.

14.

An adjuvanted, tetravalent dengue virus purified inactivated vaccine candidate induces long-lasting and protective antibody responses against dengue challenge in rhesus macaques.

Fernandez S, Thomas SJ, De La Barrera R, Im-Erbsin R, Jarman RG, Baras B, Toussaint JF, Mossman S, Innis BL, Schmidt A, Malice MP, Festraets P, Warter L, Putnak JR, Eckels KH.

Am J Trop Med Hyg. 2015 Apr;92(4):698-708. doi: 10.4269/ajtmh.14-0268. Epub 2015 Feb 2.

15.

Production and testing of dengue virus strains suitable for human infection studies.

Eckels KH.

J Infect Dis. 2014 Jun 15;209 Suppl 2:S46-8. doi: 10.1093/infdis/jiu161.

PMID:
24872395
16.

Safety and immunogenicity of a rederived, live-attenuated dengue virus vaccine in healthy adults living in Thailand: a randomized trial.

Watanaveeradej V, Gibbons RV, Simasathien S, Nisalak A, Jarman RG, Kerdpanich A, Tournay E, De La Barrerra R, Dessy F, Toussaint JF, Eckels KH, Thomas SJ, Innis BL.

Am J Trop Med Hyg. 2014 Jul;91(1):119-28. doi: 10.4269/ajtmh.13-0452. Epub 2014 May 27.

17.

Evaluation of dengue virus strains for human challenge studies.

Mammen MP, Lyons A, Innis BL, Sun W, McKinney D, Chung RC, Eckels KH, Putnak R, Kanesa-thasan N, Scherer JM, Statler J, Asher LV, Thomas SJ, Vaughn DW.

Vaccine. 2014 Mar 14;32(13):1488-94. doi: 10.1016/j.vaccine.2013.12.040. Epub 2014 Jan 24.

PMID:
24468542
18.

Experimental dengue virus challenge of human subjects previously vaccinated with live attenuated tetravalent dengue vaccines.

Sun W, Eckels KH, Putnak JR, Lyons AG, Thomas SJ, Vaughn DW, Gibbons RV, Fernandez S, Gunther VJ, Mammen MP Jr, Statler JD, Innis BL.

J Infect Dis. 2013 Mar 1;207(5):700-8. doi: 10.1093/infdis/jis744. Epub 2012 Dec 5.

PMID:
23225894
19.

A phase II, randomized, safety and immunogenicity study of a re-derived, live-attenuated dengue virus vaccine in healthy adults.

Thomas SJ, Eckels KH, Carletti I, De La Barrera R, Dessy F, Fernandez S, Putnak R, Toussaint JF, Sun W, Bauer K, Gibbons RV, Innis BL.

Am J Trop Med Hyg. 2013 Jan;88(1):73-88. doi: 10.4269/ajtmh.2012.12-0361. Epub 2012 Dec 3.

20.

Safety and immunogenicity of a tetravalent live-attenuated dengue vaccine in flavivirus-naive infants.

Watanaveeradej V, Simasathien S, Nisalak A, Endy TP, Jarman RG, Innis BL, Thomas SJ, Gibbons RV, Hengprasert S, Samakoses R, Kerdpanich A, Vaughn DW, Putnak JR, Eckels KH, Barrera Rde L, Mammen MP Jr.

Am J Trop Med Hyg. 2011 Aug;85(2):341-51. doi: 10.4269/ajtmh.2011.10-0501.

21.

Interference and facilitation between dengue serotypes in a tetravalent live dengue virus vaccine candidate.

Anderson KB, Gibbons RV, Edelman R, Eckels KH, Putnak RJ, Innis BL, Sun W.

J Infect Dis. 2011 Aug 1;204(3):442-50. doi: 10.1093/infdis/jir279.

PMID:
21742844
22.

A human challenge model for dengue infection reveals a possible protective role for sustained interferon gamma levels during the acute phase of illness.

Gunther VJ, Putnak R, Eckels KH, Mammen MP, Scherer JM, Lyons A, Sztein MB, Sun W.

Vaccine. 2011 May 17;29(22):3895-904. doi: 10.1016/j.vaccine.2011.03.038. Epub 2011 Apr 13.

PMID:
21443963
23.
24.

Phase 2 clinical trial of three formulations of tetravalent live-attenuated dengue vaccine in flavivirus-naïve adults.

Sun W, Cunningham D, Wasserman SS, Perry J, Putnak JR, Eckels KH, Vaughn DW, Thomas SJ, Kanesa-Thasan N, Innis BL, Edelman R.

Hum Vaccin. 2009 Jan-Feb;5(1):33-40. Epub 2009 Jan 27.

PMID:
18670195
25.

Comparative evaluation of three assays for measurement of dengue virus neutralizing antibodies.

Putnak JR, de la Barrera R, Burgess T, Pardo J, Dessy F, Gheysen D, Lobet Y, Green S, Endy TP, Thomas SJ, Eckels KH, Innis BL, Sun W.

Am J Trop Med Hyg. 2008 Jul;79(1):115-22.

PMID:
18606774
26.

Safety and immunogenicity of a tetravalent live-attenuated dengue vaccine in flavivirus naive children.

Simasathien S, Thomas SJ, Watanaveeradej V, Nisalak A, Barberousse C, Innis BL, Sun W, Putnak JR, Eckels KH, Hutagalung Y, Gibbons RV, Zhang C, De La Barrera R, Jarman RG, Chawachalasai W, Mammen MP Jr.

Am J Trop Med Hyg. 2008 Mar;78(3):426-33.

PMID:
18337339
27.

A Phase 2 study of a purified, inactivated virus vaccine to prevent Japanese encephalitis.

Lyons A, Kanesa-thasan N, Kuschner RA, Eckels KH, Putnak R, Sun W, Burge R, Towle AC, Wilson P, Tauber E, Vaughn DW.

Vaccine. 2007 Apr 30;25(17):3445-53. Epub 2007 Jan 4.

PMID:
17241714
28.

Protection of Rhesus monkeys against dengue virus challenge after tetravalent live attenuated dengue virus vaccination.

Sun W, Nisalak A, Gettayacamin M, Eckels KH, Putnak JR, Vaughn DW, Innis BL, Thomas SJ, Endy TP.

J Infect Dis. 2006 Jun 15;193(12):1658-65. Epub 2006 May 9.

PMID:
16703509
29.

An evaluation of dengue type-2 inactivated, recombinant subunit, and live-attenuated vaccine candidates in the rhesus macaque model.

Robert Putnak J, Coller BA, Voss G, Vaughn DW, Clements D, Peters I, Bignami G, Houng HS, Chen RC, Barvir DA, Seriwatana J, Cayphas S, Garçon N, Gheysen D, Kanesa-Thasan N, McDonell M, Humphreys T, Eckels KH, Prieels JP, Innis BL.

Vaccine. 2005 Aug 15;23(35):4442-52.

PMID:
16005749
30.

Progress in development of a live-attenuated, tetravalent dengue virus vaccine by the United States Army Medical Research and Materiel Command.

Innis BL, Eckels KH.

Am J Trop Med Hyg. 2003 Dec;69(6 Suppl):1-4. Review. No abstract available. Erratum in: Am J Trop Med Hyg. 2004 Mar;70(3):336.

PMID:
14756126
31.

Phase I trial of 16 formulations of a tetravalent live-attenuated dengue vaccine.

Edelman R, Wasserman SS, Bodison SA, Putnak RJ, Eckels KH, Tang D, Kanesa-Thasan N, Vaughn DW, Innis BL, Sun W.

Am J Trop Med Hyg. 2003 Dec;69(6 Suppl):48-60. Erratum in: Am J Trop Med Hyg. 2004 Mar;70(3):336.

PMID:
14740955
32.

Vaccination of human volunteers with monovalent and tetravalent live-attenuated dengue vaccine candidates.

Sun W, Edelman R, Kanesa-Thasan N, Eckels KH, Putnak JR, King AD, Houng HS, Tang D, Scherer JM, Hoke CH Jr, Innis BL.

Am J Trop Med Hyg. 2003 Dec;69(6 Suppl):24-31.

PMID:
14740952
33.

Phase 1 studies of Walter Reed Army Institute of Research candidate attenuated dengue vaccines: selection of safe and immunogenic monovalent vaccines.

Kanesa-Thasan N, Edelman R, Tacket CO, Wasserman SS, Vaughn DW, Coster TS, Kim-Ahn GJ, Dubois DR, Putnak JR, King A, Summers PL, Innis BL, Eckels KH, Hoke CH Jr.

Am J Trop Med Hyg. 2003 Dec;69(6 Suppl):17-23. Erratum in: Am J Trop Med Hyg. 2004 Mar;70(3):336.

PMID:
14740951
34.

Modification of dengue virus strains by passage in primary dog kidney cells: preparation of candidate vaccines and immunization of monkeys.

Eckels KH, Dubois DR, Putnak R, Vaughn DW, Innis BL, Henchal EA, Hoke CH Jr.

Am J Trop Med Hyg. 2003 Dec;69(6 Suppl):12-6. Erratum in: Am J Trop Med Hyg. 2004 Mar;70(3):336.

PMID:
14740950
35.

Formalin-inactivated whole virus and recombinant subunit flavivirus vaccines.

Eckels KH, Putnak R.

Adv Virus Res. 2003;61:395-418. Review.

PMID:
14714438
36.

Development and pre-clinical analysis of a Plasmodium falciparum Merozoite Surface Protein-1(42) malaria vaccine.

Angov E, Aufiero BM, Turgeon AM, Van Handenhove M, Ockenhouse CF, Kester KE, Walsh DS, McBride JS, Dubois MC, Cohen J, Haynes JD, Eckels KH, Heppner DG, Ballou WR, Diggs CL, Lyon JA.

Mol Biochem Parasitol. 2003 May;128(2):195-204.

PMID:
12742586
37.

Nucleotide sequence of envelope protein of Japanese encephalitis virus SA14-14-2 adapted to vero cells.

Hong SP, Yoo WD, Putnak R, Eckels KH, Rho HM, Kim SO.

DNA Seq. 2001 Dec;12(5-6):437-42.

PMID:
11913793
38.

A purified inactivated Japanese encephalitis virus vaccine made in Vero cells.

Srivastava AK, Putnak JR, Lee SH, Hong SP, Moon SB, Barvir DA, Zhao B, Olson RA, Kim SO, Yoo WD, Towle AC, Vaughn DW, Innis BL, Eckels KH.

Vaccine. 2001 Aug 14;19(31):4557-65.

PMID:
11483284
39.

Evaluation of recombinant dengue viral envelope B domain protein antigens for the detection of dengue complex-specific antibodies.

Simmons M, Porter KR, Escamilla J, Graham R, Watts DM, Eckels KH, Hayes CG.

Am J Trop Med Hyg. 1998 Feb;58(2):144-51.

PMID:
9502595
40.

Delayed-type hypersensitivity skin testing using third variable loop peptides identifies T lymphocyte epitopes in human immunodeficiency virus-infected persons.

Sitz KV, Loomis-Price LD, Ratto-Kim S, Kenner JR, Sau P, Eckels KH, Redfield RR, Birx DL.

J Infect Dis. 1997 Oct;176(4):1085-9.

PMID:
9333173
41.

Molecular analysis of dengue virus attenuation after serial passage in primary dog kidney cells.

Puri B, Nelson WM, Henchal EA, Hoke CH, Eckels KH, Dubois DR, Porter KR, Hayes CG.

J Gen Virol. 1997 Sep;78 ( Pt 9):2287-91.

PMID:
9292016
42.

Development of a purified, inactivated, dengue-2 virus vaccine prototype in Vero cells: immunogenicity and protection in mice and rhesus monkeys.

Putnak R, Barvir DA, Burrous JM, Dubois DR, D'Andrea VM, Hoke CH, Sadoff JC, Eckels KH.

J Infect Dis. 1996 Dec;174(6):1176-84.

PMID:
8940206
43.

T cell activation in vivo by dengue virus infection.

Kurane I, Innis BL, Hoke CH Jr, Eckels KH, Meager A, Janus J, Ennis FA.

J Clin Lab Immunol. 1995;46(1):35-40.

PMID:
9363590
44.

A live attenuated dengue-1 vaccine candidate (45AZ5) passaged in primary dog kidney cell culture is attenuated and immunogenic for humans.

Edelman R, Tacket CO, Wasserman SS, Vaughn DW, Eckels KH, Dubois DR, Summers PL, Hoke CH.

J Infect Dis. 1994 Dec;170(6):1448-55.

PMID:
7995984
45.

Quantitative relationship between oral temperature and severity of illness following inoculation with candidate attenuated dengue virus vaccines.

Mackowiak PA, Wasserman SS, Tacket CO, Vaughn DW, Eckels KH, Dubois DR, Hoke CH, Edelman R.

Clin Infect Dis. 1994 Nov;19(5):948-50.

PMID:
7893886
46.

Immunization of monkeys with baculovirus-dengue type-4 recombinants containing envelope and nonstructural proteins: evidence of priming and partial protection.

Eckels KH, Dubois DR, Summers PL, Schlesinger JJ, Shelly M, Cohen S, Zhang YM, Lai CJ, Kurane I, Rothman A, et al.

Am J Trop Med Hyg. 1994 Apr;50(4):472-8.

PMID:
8166355
48.

Solid-phase antibody capture hemadsorption assay for detection of hepatitis A virus immunoglobulin M antibodies.

Summers PL, Dubois DR, Cohen WH, Macarthy PO, Binn LN, Sjogren MH, Snitbhan R, Innis BL, Eckels KH.

J Clin Microbiol. 1993 May;31(5):1299-302.

49.

Hepatitis A in the US Army: epidemiology and vaccine development.

Hoke CH Jr, Binn LN, Egan JE, DeFraites RF, MacArthy PO, Innis BL, Eckels KH, Dubois D, D'Hondt E, Sjogren MH, et al.

Vaccine. 1992;10 Suppl 1:S75-9.

PMID:
1335665
50.

New approaches to flavivirus vaccine development.

Schlesinger JJ, Putnak JR, Eckels KH.

Biotechnology. 1992;20:289-307. Review. No abstract available.

PMID:
1318137

Supplemental Content

Loading ...
Support Center